AdvanCell Closes A$18M Series B Funding Led by Morningside
14.9.2022 17:16:00 EEST | Business Wire | Press release
AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.
Andrew Adamovich, CEO and Founder of AdvanCell noted, “We are very pleased with our progress to date and delighted that we will continue our rapid growth with the support of our shareholders. We have had a long-term relationship with our lead investor, Morningside, and are excited to come closer still to our goal to 'Change the Course of Cancer Treatment.'”
Targeted Alpha Therapies represent the most exciting opportunity to treat currently untreatable cancers. The technology harnesses the natural decay and radiochemical properties of certain elements, in combination with specific targeting molecules, to selectively deliver cell-killing radiation to the tumour cell. AdvanCell believes this precise and powerful treatment will rapidly become a leading pillar of cancer treatment, providing treatments for diseases for which there are currently no effective options. Targeted Alpha Therapies demonstrate incredible efficacy, however widespread adoption and large commercial product launches require a scalable and reliable global isotope supply. AdvanCell was established to solve this problem.
AdvanCell’s ability to produce isotope on-demand and at scale, and its in-house radiopharmaceutical manufacturing expertise positions AdvanCell to play a leading role in this rapidly growing market. With additional support from NSW Health Medical Devices Fund and the Federal government’s Research & Development Tax Incentive, AdvanCell has developed a world-first scalable manufacturing platform to produce alpha-emitting isotopes for research, pre-clinical and clinical use and to advance its own and its partners' radiopharmaceutical products.
Anthony Aiudi from Morningside commented, “AdvanCell is leveraging its ability to make alpha isotopes at scale and in clinically useful amounts along with its radiochemistry expertise, to develop an exciting portfolio of Targeted Alpha Therapies. Targeted Alpha Therapies hold incredible promise however their development has been hamstrung by a lack of radioisotope supply. Together with the team at AdvanCell, we look forward to writing a new chapter in oncology, to target large patient populations with significant unmet needs.”
Mr Aiudi has been appointed to the Board of AdvanCell, joining Mr Adamovich, Bill Ferris AC, co-founder of CPE Capital, Adrian “Adi” Patterson, former Australian Nuclear Science and Technology Organisation (ANSTO) CEO and Kevin Cameron, CEO of Ionetix.
Bill Ferris AC, Chair remarked, “Our executive team has articulated a credible pre-clinical and clinical pathway for the delivery of the Company’s novel Targeted Alpha Therapies. Having successfully developed the manufacturing platform essential for the reliable and scalable supply of isotopes, the Company is on schedule with its pre-clinical work and is now moving into first-in-human trials. AdvanCell is on track to become a leading radiopharmaceutical company with a platform technology enabling novel cancer treatments.”
About AdvanCell
AdvanCell is a radiopharmaceutical company developing next-generation cancer treatment. AdvanCell’s Targeted Alpha Therapies are powered by a platform technology – a world-first alpha isotope generator that addresses the greatest unmet need in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell has a world-class team and is honoured to be advised by an outstanding Board of Directors and Scientific Advisory Board. For more information visit www.advancell.com.au
About Morningside
Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai and London, the firm invests globally. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. Morningside partners with academic founders and entrepreneurs to build world-class companies that want to markedly improve the current state of medicine today and ultimately, the lives of patients. In addition to its investment activities, Morningside Ventures is strongly committed to social responsibility. For more information visit www.morningside.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005846/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lincotek Appoints New Global General Manager for Its Medical Division7.4.2026 11:08:00 EEST | Press release
Lincotek today announced the appointment of Gianluca Fioravanti as Global General Manager of its Medical Division - a global solution provider for the orthopedic market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407710572/en/ Gianluca Fioravanti, Global GM Lincotek’s Medical Division Reporting directly to Group CEO Andrea Colombo, Fioravanti assumed the role as of April 7 and will help drive the business forward. He will lead the development and execution of the company’s global growth strategy, while ensuring its seamless operational implementation across all regions. This strategic appointment reflects Lincotek’s commitment to enhance the value it delivers to customers, strengthening its ability to serve them better. Fioravanti brings more than 25 years of international experience to the Group, having held senior leadership roles across operations, engineering and general management in the medical sector. With a de
Toshiba’s Breakthrough Algorithm Harnesses Edge of Chaos to Dramatically Boost Performance of its Quantum‑Inspired Computer7.4.2026 10:00:00 EEST | Press release
Toshiba Corporation has developed a breakthrough algorithm that dramatically boosts the performance of the Simulated Bifurcation Machine (SBM), its proprietary quantum‑inspired combinatorial optimization computer. The new algorithm significantly improves the probability of obtaining an optimal solution or a known best solution within a limited number of trials—referred to as the success probability, a key benchmark for evaluating combinatorial optimization technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407918434/en/ Figure 1: Results demonstrating that the newly developed third‑generation SB algorithm can find the known best solution with nearly 100% probability at the edge of chaos for a fully connected 2,000‑spin Ising problem. The SBM is designed to solve large‑scale combinatorial optimization problems in a wide range of fields, including new drug discovery, delivery route optimization, and investment por
Budweiser Honors 40 Years of FIFA World Cup™ Legacy with Limited-Edition Collectible Pack and Nostalgia-Themed Platform7.4.2026 10:00:00 EEST | Press release
Today, Budweiser is celebrating 40 years as the Official Beer Sponsor of the FIFA World Cup™ with the launch of the largest limited-edition collectible pack ever – the Budweiser® FIFA World Cup™ Anniversary Pack* – bringing to life 11 bold design tributes to every tournament since 1986, and the centerpiece of a new nostalgia driven global platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407304059/en/ Budweiser® FIFA World Cup™ Anniversary Pack Throughout history, Budweiser has played an important role in some of football’s most unforgettable celebrations, from last-minute goals to trophy lifts seen around the world. These moments of “Budstalgia” [Budweiser + nostalgia] are the inspiration for the brand’s newest platform, brought to life through a new collectible design, a global film titled “The Big Drop,” distinctive out-of-home creative, and an era-inspired digital hub. “For 40 years, Budweiser has been part of
Ardabelle Reveals a €7 Trillion Challenge for Europe: Invest Now or Lose a Generation of Competitiveness7.4.2026 08:30:00 EEST | Press release
Europe is navigating a period of intense turbulence, where geopolitical crises, pressure on critical raw materials, and climate‑related shocks are reinforcing one another. This polycrisis is no longer cyclical: it is structurally reshaping the continent’s value chains and testing its industrial competitiveness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260406787383/en/ Europe's Choice: €27T Coordinated Growth or €20T Fragmented Decline by 2050 In this context, Ardabelle is releasing Greening the Arteries of Industry, a groundbreaking study that quantifies for the first time the economic gap between a Europe that endures and a Europe that invests. Conducted under the scientific supervision of economist Xavier Jaravel, this work represents the first attempt to model, in an integrated way, industrial resilience, ecological transition, and European competitiveness through 2035 - 2050. The study was presented under the high
Tigo Energy Launches New GO Optimized Energy Storage System in European Residential Market7.4.2026 07:00:00 EEST | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced availability of the Tigo GO Battery, a next-generation energy storage system and the latest addition to the Tigo GO optimized product line in Europe, joining the GO EV Charger and GO Junction for heat pump integration. The system delivers expandable energy storage capacity of up to 47.9kWh, faster installation via lightweight plug-and-play modules, and cold-weather operation down to -30°C. Installer preorders are currently available, with product shipping commencing in June 2026. The new GO Battery arrives as several European countries set new all-time single-day records for solar energy production, and global solar installations grew by 11% between 2024 and 2025. The Tigo GO Battery serves European market demand with an optimized modular architecture built on 3.68kWh battery units that installers can configure from 7.3kWh for compact installati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom